SOURCE-LINKED STUDY SUMMARY
Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity: A Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind trial tested urolithin A effects on peripheral and brain vascular responses.
- Who / model studied
- 50 middle-aged adults with obesity; 7 were lost to follow-up.
- Studied dose & schedule
- Urolithin A 1000 mg versus placebo for 4 weeks.
- What the study found
- The primary flow-mediated-dilation outcome and other peripheral vascular outcomes did not improve significantly. A secondary task-evoked brain-hemodynamic signal improved, while task performance remained unchanged.
- Limitations & context
- Single-site, short trial with attrition. A brain blood-flow response is not evidence of better cognition or disease prevention. Abstract-based findings; publisher verified first-online date.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jamanetworkopen.2026.38047